Equities research analysts predict that Tcr2 Therapeutics Inc (NASDAQ:TCRR) will report earnings per share of ($0.65) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Tcr2 Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.62) and the lowest estimate coming in at ($0.67). Tcr2 Therapeutics posted earnings per share of ($16.22) in the same quarter last year, which suggests a positive year over year growth rate of 96%. The company is expected to announce its next quarterly earnings report on Monday, April 6th.
According to Zacks, analysts expect that Tcr2 Therapeutics will report full-year earnings of ($5.10) per share for the current fiscal year, with EPS estimates ranging from ($6.56) to ($4.32). For the next year, analysts expect that the company will report earnings of ($2.76) per share, with EPS estimates ranging from ($3.21) to ($1.91). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Tcr2 Therapeutics.
Tcr2 Therapeutics (NASDAQ:TCRR) last issued its earnings results on Tuesday, November 12th. The company reported ($0.58) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.03).
A number of equities analysts recently weighed in on the stock. ValuEngine downgraded shares of Tcr2 Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Zacks Investment Research downgraded shares of Tcr2 Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, November 16th. Finally, HC Wainwright restated a “buy” rating and set a $19.00 target price on shares of Tcr2 Therapeutics in a report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $25.00.
In other Tcr2 Therapeutics news, major shareholder Morana Jovan-Embiricos sold 139,989 shares of Tcr2 Therapeutics stock in a transaction on Monday, December 9th. The shares were sold at an average price of $17.65, for a total transaction of $2,470,805.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 154,511 shares of company stock valued at $2,708,823. Company insiders own 39.07% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the business. Barclays PLC boosted its position in Tcr2 Therapeutics by 402.1% during the third quarter. Barclays PLC now owns 5,885 shares of the company’s stock worth $89,000 after purchasing an additional 4,713 shares during the period. Parametric Portfolio Associates LLC boosted its position in Tcr2 Therapeutics by 23.5% during the second quarter. Parametric Portfolio Associates LLC now owns 35,044 shares of the company’s stock worth $501,000 after purchasing an additional 6,672 shares during the period. Rhumbline Advisers bought a new position in Tcr2 Therapeutics during the third quarter worth $162,000. California State Teachers Retirement System boosted its position in Tcr2 Therapeutics by 568.2% during the third quarter. California State Teachers Retirement System now owns 18,254 shares of the company’s stock worth $274,000 after purchasing an additional 15,522 shares during the period. Finally, EcoR1 Capital LLC bought a new position in Tcr2 Therapeutics during the second quarter worth $231,000. 42.15% of the stock is owned by hedge funds and other institutional investors.
TCRR traded up $0.41 during trading on Tuesday, reaching $14.50. 58,300 shares of the stock were exchanged, compared to its average volume of 95,878. The stock has a market cap of $370.12 million and a P/E ratio of -0.15. Tcr2 Therapeutics has a twelve month low of $10.04 and a twelve month high of $25.47. The stock’s 50 day moving average price is $16.08 and its two-hundred day moving average price is $15.49.
Tcr2 Therapeutics Company Profile
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.
See Also: Stock Portfolio Tracker
Get a free copy of the Zacks research report on Tcr2 Therapeutics (TCRR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.